Equipment review: The molecular adsorbents recirculating system (MARS®)

Table 2 Clinical and laboratory effects of MARS therapy

		Patient 1		Patient 2		Patient 3		Patient 4		Patient 5
Parameter	Normal range	Before	After	Before	After	Before	After	Before	After	Before	After
Noradrenaline, μg kg^-1 min^-1		0.22	0.02	0.06	0.16	0	0	0.22	0.10	0.32	0.06
Creatinine	60–110 μM	307	142	132	239	171	234	241	144	164	107
Urea	2.9–7.1 mM	21	13	16	22	1	6	11	29	15	17
Ammonia	15–50 μM	67	47
HE grade		4	3					3	1	3	2
Bilirubin	<25 μM	161	210	654	528	260	182	484	137	510	326
Bile acids	0–6 μM	75	75					27	16	202	67
AA/β-OH-But		4.2	6.8					1.3	8	4	4.5
PDR ICG	>16% min^-1	4.4	5.5	4.3	5.2	4.3	5.4	5.6	5.2
Duration of treatment, h		24, 16		15, 13		5, 6		12, 16, 20		6, 6, 6
Outcome		ICU D/C, died in ward		Died in ICU		ICU D/C, died in ward		D/C home		Died in ICU

AA/β-OH-But, ratio of arterial acetoacetate to β-hydroxybutyrate (ketone body); D/C, discharged; HE, hepatic encephalopathy; ICU, intensive care unit; PDR ICG, plasma disappearance rate of indocyanine green (measured after an intravenous dose of 0.5 mg kg^-1 body weight with a non-invasive transcutaneous probe [Pulsion Medical System AG, Munich]).